|
Wed, 12/21/2022 - 06:11 |
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes |
Alnylam |
|
Wed, 07/27/2022 - 14:19 |
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure |
Lexicon Pharmac... |
|
Wed, 07/27/2022 - 06:49 |
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity |
Alnylam |
|
Tue, 05/31/2022 - 12:28 |
Important Updates to the Standards of Medical Care in Diabetes2022 Incorporate New Evidence |
American Diabet... |
|
Thu, 01/27/2022 - 18:44 |
RCPE Pakistan: Updates in Clinical Medicine |
RCPE |
|
Tue, 11/16/2021 - 05:59 |
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes |
Viatris |
|
Mon, 11/15/2021 - 16:19 |
Conemaugh Memorial Medical Centers Internal Medicine Clinic Welcomes Dr. Chudamani Giri |
Conemaugh Physi... |
|
Fri, 09/24/2021 - 04:26 |
Timme-Laragy to Investigate Effects of Environmental Toxicants on Pancreatic Development |
University of M... |
|
Wed, 09/22/2021 - 03:12 |
Setting global targets could cut impact of diabetes in developing countries |
University of B... |
|
Mon, 09/13/2021 - 12:11 |
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th |
Vertex |
|
Sun, 08/29/2021 - 22:59 |
Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care |
Lexicon Pharmac... |
|
Tue, 08/24/2021 - 12:02 |
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies |
Vertex |
|
Wed, 08/04/2021 - 13:44 |
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer |
Vertex |
|
Thu, 07/29/2021 - 13:04 |
Dr. Mark Peterson named recipient of 2021 AVMA Lifetime Excellence in Research Award |
AVMA |
|
Wed, 07/28/2021 - 13:54 |
FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes |
FDA |
|
Sun, 07/18/2021 - 19:49 |
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain |
Vertex |
|
Tue, 06/29/2021 - 01:54 |
Walmart Revolutionizes Insulin Access & Affordability for Patients With Diabetes With the Launch of the First and Only Private Brand Analog Insulin |
Wal Mart Stores |
|
Mon, 06/28/2021 - 00:26 |
Vertex Announces National Reimbursement Agreement in France for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients |
Vertex |
|
Sun, 06/27/2021 - 22:25 |
Weekly Injection of Glucose-Reducing Drug Offers Safe and Effective Way To Significantly Reduce Cardiorenal Events for People With Type 2 Diabetes |
American Diabet... |
|
Fri, 06/25/2021 - 05:57 |
Unmanaged Diabetes Associated with Greater COVID-19 Severity |
American Diabet... |
|
Thu, 06/24/2021 - 23:56 |
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO, SYMKEVI and Additional Indications of ORKAMBI and KALYDECO for Eligible Patients With Cystic Fibrosis |
Vertex |
|
Thu, 06/24/2021 - 15:53 |
American Diabetes Association Presents Latest COVID-19 Findings with Five Comprehensive Panel Symposia at the 81st Scientific Sessions |
American Diabet... |
|
Thu, 06/17/2021 - 21:59 |
Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation |
Vertex |
|
Thu, 06/10/2021 - 11:46 |
Conemaugh Memorial Medical Centers Internal Medicine Clinic Welcomes Khandakar Raihan Hussain, MD |
Conemaugh Physi... |
|
Wed, 05/19/2021 - 11:56 |
FDA In Brief: FDA Issues Draft Guidance on Early Clinical Studies for Certain Medical Devices to Improve Glycemic Control for Type 2 Diabetes |
FDA |
